Free tool
FAERS Monitor: Veppanu
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 219835 or its brand name (Veppanu, Vepdegestrant). Reports on generic versions are filed under their own applications.
Reports
7
Serious
7
100% of reports
Hospitalization
2
Death reported
1
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- neutropenia2
- blood pressure decreased1
- blood sodium decreased1
- breast cancer1
- death1
- fall1
- localised oedema1
- malignant neoplasm progression1
- product dose omission issue1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2024 | 1 |
| 2026 | 6 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,152 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| localised oedema | 1 | 649.5 | 105.8 | 161 |
| blood sodium decreased | 1 | 159.5 | 26.0 | 39 |
| blood pressure decreased | 1 | 45.2 | 7.4 | 10 |
| neutropenia | 2 | 44.2 | 13.7 | 47 |
| breast cancer | 1 | 32.2 | 5.3 | 7 |
| malignant neoplasm progression | 1 | 29.3 | 4.8 | 6 |
| product dose omission issue | 1 | 10.2 | 1.7 | 2 |
| fall | 1 | 9.0 | 1.5 | 1 |
| death | 1 | 3.5 | 0.6 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.